Abstract
Indium-111-labeled monoclonal antibody directed against prostate-specific antigen was injected into ten patients with known prostatic carcinoma, nine with metastatic disease. The monoclonal antibody scan was compared to the standard technetium bone scan, and both were correlated to clinical status and to 2-year follow-up. The ratio of target-to-nontarget activity and pharmacokinetics of the radiolabeled antibody approach may be used for staging and may be developed as a therapeutic adjuvant.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 209-220 |
| Number of pages | 12 |
| Journal | Prostate |
| Volume | 14 |
| Issue number | 3 |
| State | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Development of monoclonal antibody imaging of metastatic prostatic carcinoma. / Meyers, Frederick J; Denardo, S. J.; Macey, D.; deVere White, Ralph W; Unger, M.
In: Prostate, Vol. 14, No. 3, 1989, p. 209-220.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Development of monoclonal antibody imaging of metastatic prostatic carcinoma
AU - Meyers, Frederick J
AU - Denardo, S. J.
AU - Macey, D.
AU - deVere White, Ralph W
AU - Unger, M.
PY - 1989
Y1 - 1989
N2 - Indium-111-labeled monoclonal antibody directed against prostate-specific antigen was injected into ten patients with known prostatic carcinoma, nine with metastatic disease. The monoclonal antibody scan was compared to the standard technetium bone scan, and both were correlated to clinical status and to 2-year follow-up. The ratio of target-to-nontarget activity and pharmacokinetics of the radiolabeled antibody approach may be used for staging and may be developed as a therapeutic adjuvant.
AB - Indium-111-labeled monoclonal antibody directed against prostate-specific antigen was injected into ten patients with known prostatic carcinoma, nine with metastatic disease. The monoclonal antibody scan was compared to the standard technetium bone scan, and both were correlated to clinical status and to 2-year follow-up. The ratio of target-to-nontarget activity and pharmacokinetics of the radiolabeled antibody approach may be used for staging and may be developed as a therapeutic adjuvant.
UR - http://www.scopus.com/inward/record.url?scp=0024390192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024390192&partnerID=8YFLogxK
M3 - Article
VL - 14
SP - 209
EP - 220
JO - Prostate
JF - Prostate
SN - 0270-4137
IS - 3
ER -